These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 38659488

  • 1. Real-world efficacy and safety of tofacitinib treatment in Asian patients with ulcerative colitis.
    Kojima K, Watanabe K, Kawai M, Yagi S, Kaku K, Ikenouchi M, Sato T, Kamikozuru K, Yokoyama Y, Takagawa T, Shimizu M, Shinzaki S.
    World J Gastroenterol; 2024 Apr 07; 30(13):1871-1886. PubMed ID: 38659488
    [Abstract] [Full Text] [Related]

  • 2. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis.
    Lair-Mehiri L, Stefanescu C, Vaysse T, Laharie D, Roblin X, Rosa I, Treton X, Abitbol V, Amiot A, Bouguen G, Dib N, Fumery M, Pariente B, Carbonnel F, Peyrin-Biroulet L, Simon M, Viennot S, Bouhnik Y.
    Dig Liver Dis; 2020 Mar 07; 52(3):268-273. PubMed ID: 31732444
    [Abstract] [Full Text] [Related]

  • 3. Effect of Tofacitinib on One-Year Colectomy Risk in Anti-TNF Refractory Ulcerative Colitis: A Prospective Multicenter Italian Study.
    Carvalhas Gabrielli AM, Ferretti F, Monico CM, Tombetti E, Maconi G, Romeo S, Piazza O Sed N, Caprioli F, Mazzola AM, Alicante S, Bertè R, Lolli E, Scribano ML, Buscarini E, Ricci C, Carmagnola S, Ardizzone S, Cannatelli R.
    Dig Dis Sci; 2024 May 07; 69(5):1785-1792. PubMed ID: 38530500
    [Abstract] [Full Text] [Related]

  • 4. Real-World Experience with Tofacitinib in IBD at a Tertiary Center.
    Weisshof R, Aharoni Golan M, Sossenheimer PH, El Jurdi K, Ollech JE, Pekow J, Cohen RD, Sakuraba A, Dalal S, Rubin DT.
    Dig Dis Sci; 2019 Jul 07; 64(7):1945-1951. PubMed ID: 30734234
    [Abstract] [Full Text] [Related]

  • 5. Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience.
    Honap S, Chee D, Chapman TP, Patel M, Kent AJ, Ray S, Sharma E, Kennedy J, Cripps S, Walsh A, Goodhand JR, Ahmad T, Satsangi J, Irving PM, Kennedy NA, LEO [London, Exeter, Oxford] IBD Research Consortium .
    J Crohns Colitis; 2020 Oct 05; 14(10):1385-1393. PubMed ID: 32280965
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry.
    Chaparro M, Garre A, Mesonero F, Rodríguez C, Barreiro-de Acosta M, Martínez-Cadilla J, Arroyo MT, Manceñido N, Sierra-Ausín M, Vera-Mendoza I, Casanova MJ, Nos P, González-Muñoza C, Martínez T, Boscá-Watts M, Calafat M, Busquets D, Girona E, Llaó J, Martín-Arranz MD, Piqueras M, Ramos L, Surís G, Bermejo F, Carbajo AY, Casas-Deza D, Fernández-Clotet A, García MJ, Ginard D, Gutiérrez-Casbas A, Hernández L, Lucendo AJ, Márquez L, Merino-Ochoa O, Rancel FJ, Taxonera C, López Sanromán A, Rubio S, Domènech E, Gisbert JP.
    J Crohns Colitis; 2021 Jan 13; 15(1):35-42. PubMed ID: 32969471
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial.
    Mukherjee A, Hazra A, Smith MK, Martin SW, Mould DR, Su C, Niezychowski W.
    Br J Clin Pharmacol; 2018 Jun 13; 84(6):1136-1145. PubMed ID: 29377257
    [Abstract] [Full Text] [Related]

  • 12. Clinical and Endoscopic Outcomes Through 78 Weeks of Tofacitinib Therapy for Ulcerative Colitis in a US Cohort.
    Dalal RS, Sharma PP, Bains K, Pruce JC, Allegretti JR.
    Inflamm Bowel Dis; 2024 Oct 03; 30(10):1707-1713. PubMed ID: 37843044
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis.
    Colombel JF, Osterman MT, Thorpe AJ, Salese L, Nduaka CI, Zhang H, Lawendy N, Friedman GS, Quirk D, Su C, Reinisch W.
    Clin Gastroenterol Hepatol; 2022 Jan 03; 20(1):116-125.e5. PubMed ID: 33039585
    [Abstract] [Full Text] [Related]

  • 15. Real world evidence on the effectiveness and safety of tofacitinib in ulcerative colitis in Lebanon.
    Sharara AI, Alrazim A, Saniour P, Daniel F, Rached AA, Bahr A, Azar C, Geagea A, Ghoubar M.
    BMC Gastroenterol; 2024 Oct 04; 24(1):349. PubMed ID: 39367371
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Tofacitinib is an effective treatment for moderate to severe ulcerative colitis, and intestinal ultrasound can discriminate response from non-response: a pragmatic prospective real-world study.
    Ollech JE, Eran-Banai H, Goren I, Sharar Fischler T, Avni-Biron I, Snir Y, Broitman Y, Cohen S, Friedenberg A, Pauker MH, Dotan I, Yanai H.
    Ann Med; 2024 Dec 04; 56(1):2358183. PubMed ID: 38813808
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.